25 completed, 6 terminated, 2 no longer available, 1 approved for marketing. 18 Phase 2, 12 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 14, Terminated 3, Withdrawn 1 |
| Phase 1 | 12 | Completed 11, Withdrawn 1 |
| Phase 3 | 4 | Completed 2, Terminated 2 |
Follow Ariad Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib Brigatinib - ALK-positive Advanced NSCLC | Phase 2 | Completed | Ariad Pharmaceuticals | 103 | 2019-01-31 | 2025-07-31 |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL | Terminated | Ariad Pharmaceuticals | 3 | 2018-03-02 | 2024-04-04 | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Ponatinib, 5-azacytidine, Phone Calls - Leukemia, FLT3-Mutated Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2016-09-01 | 2017-06-02 | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Brigatinib, Crizotinib - Non-small Cell Lung Cancer, Lung Cancer | Phase 3 | Completed | Ariad Pharmaceuticals | 275 | 2016-05-26 | 2021-08-20 |
| A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID - Chronic Phase Chronic Myeloid Leukemia | Phase 3 | Terminated | Ariad Pharmaceuticals | 44 | 2015-12-31 | 2021-11-26 |
| A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Brigatinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Ariad Pharmaceuticals | 222 | 2014-06-04 | 2021-03-15 |
| Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Ponatinib - Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer | Phase 2 | Completed | University of Colorado, Denver | 171 | 2013-09-24 | 2022-02-11 |
| A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Ponatinib - GIST | Phase 2 | Completed | Ariad Pharmaceuticals | 45 | 2013-06-05 | 2018-05-18 |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) ponatinib - Phase 1, ponatinib - Phase 2 - Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Phase 1 / Phase 2 | Completed | Ariad Pharmaceuticals | 35 | 2012-08-31 | 2022-06-13 |
| Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) ponatinib, imatinib (Gleevec/ Glivec) - Chronic Myeloid Leukemia | Phase 3 | Terminated | Ariad Pharmaceuticals | 307 | 2012-06-01 | 2014-11-17 |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Ponatinib - Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 51 | 2012-04-01 | 2025-12-08 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) Brigatinib - Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Ariad Pharmaceuticals | 137 | 2011-09-20 | 2021-08-17 |
| Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Ponatinib - Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia | Phase 2 | Completed | Ariad Pharmaceuticals | 449 | 2010-09-30 | 2021-02-02 |
| Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046) ridaforolimus - Healthy Volunteers, Hepatic Insufficiency | Phase 1 | Completed | Merck Sharp & Dohme LLC | 19 | 2010-01-01 | 2015-04-29 |
| Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) Ridaforolimus - Sarcoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 50 | 2009-11-01 | 2015-04-30 |
| A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) Lead-In Ridaforolimus, Comparator: Blinded Ridaforolimus, Comparator: Blinded Placebo - Non-Small Cell Lung Cancer | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 80 | 2009-03-01 | 2015-01-21 |
| Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) Ridaforolimus Tablet, Ridaforolimus Intravenous (IV) Infusion - Advanced Cancers | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 7 | 2009-02-01 | 2019-02-18 |
| Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer ridaforolimus, gene expression analysis, immunohistochemistry staining method - Endometrial Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 35 | 2008-11-13 | 2023-08-04 |
| Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) ridaforolimus, bevacizumab - Solid Tumor | Phase 1 | Completed | Merck Sharp & Dohme LLC | 17 | 2008-10-01 | 2015-02-13 |
| Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) ridaforolimus (MK8669), Comparator: Placebo, open-label ridaforolimus (MK8669) - Prostate Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 22 | 2008-10-01 | 2015-08-19 |
Showing 20 of 35. Sign in to see all of them.
Neoplasms (11) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Leukemia (8) · Carcinoma, Non-Small-Cell Lung (6) · Leukemia, Myeloid (4) · Sarcoma (4) · Bone Marrow Diseases (3) · Hematologic Diseases (3) · Lung Neoplasms (3) · Lymphoma (3) · Myeloproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Adenocarcinoma (2) · Carcinoma (2) · Carcinoma, Large Cell (2)
ridaforolimus (17) · ponatinib (11) · brigatinib (5) · Azacitidine (1) · BID protein, human (1) · Bevacizumab (1) · Crizotinib (1) · Doxorubicin (1) · Gene Expression Profiling (1) · Imatinib Mesylate (1) · Immunohistochemistry (1) · dalotuzumab (1) · nilotinib (1)
United States (15) · Australia (4) · Canada (4) · France (4) · Germany (4) · Italy (4) · Netherlands (4) · South Korea (4) · Spain (4) · Sweden (4) · Austria (3) · Belgium (3) · Hong Kong (3) · Singapore (3) · Taiwan (3)
Frank Haluska, M.D., Ph.D. (3) · Frank Haluska, M.D. (2) · Amit M. Oza, MD (1) · Frank Haluska, MD, PhD (1) · Jorge Cortes, MD (1) · Naval Daver, MD (1) · Ross D Camidge, MD, PhD (1)
PMID 34699069, PMID 22067397, PMID 29768119, PMID 18202410, PMID 18451242, PMID 22037923, PMID 22695254, PMID 22825216, PMID 23190221, PMID 23211938, PMID 23403817, PMID 23411383, PMID 23615181, PMID 23715582, PMID 23921574, PMID 24180494, PMID 25173583, PMID 25320355, PMID 26436130, PMID 27083332, PMID 27836716, PMID 28444644, PMID 28501139, PMID 28835440, PMID 29567798, PMID 30280657, PMID 30885996, PMID 31125274, PMID 32780660, PMID 33569983, PMID 34991679, PMID 36054756, PMID 36096442, PMID 39707229, PMID 41110382, PMID 41410381, PMID 41740899
2015 (2), 2004 (1), 2018 (1)